Application of radiolabeled peptides in tumor imaging and therapy.
Cancer
Chelator
Radiolabeled peptides
Radionuclide
Tumor imaging and therapy
Journal
Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521
Informations de publication
Date de publication:
01 Oct 2020
01 Oct 2020
Historique:
received:
08
05
2020
revised:
24
07
2020
accepted:
01
08
2020
pubmed:
8
8
2020
medline:
2
10
2020
entrez:
8
8
2020
Statut:
ppublish
Résumé
Scientists are looking for new therapies to cope with the rise in cancer worldwide. Since cancer cells overexpress peptide receptors and owing to small size, easy uptake by tumor cells, easy preparation, and with no toxicity, the use of radiolabeled peptides with high specificity and affinity for accurate imaging and therapy has attracted much attention. To develop an ideal imaging or treatment radiolabeled peptide, there are some aspects in the components of radiolabeled peptide including radionuclide, peptide, chelator, and spacer that should be considered. Some peptides, including somatostatin, RGD, neurotensin, bombesin, exendin, vasoactive intestinal peptide, and gastrin are currently under (pre)clinical investigations. Today, nanoparticles are suitable tools for targeting peptide for molecular imaging and therapy of tumors with low toxicity. This paper presents some essential aspects in developing a valuable radiolabeled peptide and some radiolabeled peptides with regard to their applications in tumor imaging and therapy in pre-clinical and clinical phases.
Identifiants
pubmed: 32758623
pii: S0024-3205(20)30958-9
doi: 10.1016/j.lfs.2020.118206
pii:
doi:
Substances chimiques
Inflammation Mediators
0
Peptide Fragments
0
Radiopharmaceuticals
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
118206Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that there are no conflicts of interest.